Semaglutide, known for its brand names Ozempic and Wegovy, has become a popular choice for weight loss and managing type 2 diabetes
At 80 weeks, participants on 4mg of retatrutide lost an average of 17.6% of their body weight, compared with 23.7% on 9mg, 25.0% on 12mg and 3.9% on placebo, the study results revealed
Clinical studies Despite their thriving role in the treatment of obesity 214 , only seven studies investigated the effects of GLP-1RAs in eating disorders (Table 6), including some on their psychopathology in comorbid obesity 215,216,217 and others specifically in binge-eating disorder (BED) 217,218,219,220 , and we could not find any ongoing trial in this area
Coverage for diabetes differs from weight loss
I en vergripande fas-2-studie noterades HbA1c-snkning p upp till 2,2 procentenheter och 16,9 % viktnedgng efter 36 veckor
Emerging Role of GLP-1 Receptor Agonists for the Treatment of MASH Abstract: Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes, and other metabolic disorders
